SECURITIES AND EXCHANGE COMMISSION

	WASHINGTON, DC 20549
	SCHEDULE 13G
	UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No)*
	Autolus Therapeutics plc (Name of Issuer)
	Ordinary Shares (Title of Class of Securities)
	05280R100** (CUSIP Number)
	December 13, 2021 (Date of Event Which Requires Filing of this Statement)
Che	eck the appropriate box to designate the rule pursuant to which this Schedule is filed:
	☐ Rule 13d-1(b)
	⊠ Rule 13d-1(c)
	☐ Rule 13d-1(d)
*	The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with and for any subsequent amendment containing information which would alter the disclosures provided in

- The remainder of this co h respect to the subject class of securities, and for any subsequent a n a prior cover page.
- There is no CUSIP number assigned to the ordinary shares. CUSIP number 05280R 100 has been assigned to the American Depositary Shares of the Issuer, which are quoted on the Nasdaq Global Select Market under the symbol "AUTL." Each American Depositary Share represents the right to receive one Ordinary Share of the Issuer.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1.	Names	of F	Leporting Persons
	Frazier	Life	Sciences Public Fund L.P.
2.			Appropriate Box if a Member of a Group (see instructions)
	(a) 🗆		(b) ⊠
3.	SEC U	SE (DNLY
4.	Citizen	shin	or Place of Organization
٦.	Citizen	ыпр	of Flace of Organization
	Delawa		
		5.	Sole Voting Power
Nu	mber of		0 shares
S	hares	6.	Shared Voting Power
	eficially ned by		3,009,706 shares (1)
	Each	7.	Sole Dispositive Power
	porting erson		0 shares
7	With:	8.	Shared Dispositive Power
			3,009,706 shares (1)
9.	Aggreg	gate 1	Amount Beneficially Owned by Each Reporting Person
	3,009,7	706 s	hares (1)
10.			e Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)
11.	_	t of (Class Represented by Amount in Row 9
	4.1% (2)	
12.	,		porting Person (see instructions)
		-,	
	PN		

- (1) Consists of 3,009,706 Ordinary Shares held directly by Frazier Life Sciences Public Fund L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund L.P.
- (2) Based on 72,918,994 Ordinary Shares outstanding on September 30, 2021 as set forth in the Issuer's Unaudited Condensed Consolidated Interim Financial Statements for the Three and Nine Months Ended September 30, 2021, which was included as Exhibit A to the Issuer's Form 6-K filed with the SEC on November 3, 2021.

1.	Names	of F	Reporting Persons
	FHML	SP, I	L.P.
2.			Appropriate Box if a Member of a Group (see instructions)
	(a) 🗆		(b) ⊠
3.	SEC U	SE C	DNLY
4.	Citizen	ship	or Place of Organization
	Delawa	are	
		5.	Sole Voting Power
Nu	mber of		0 shares
S	hares	6.	Shared Voting Power
	eficially ned by		3,009,706 shares (1)
	Each porting	7.	Sole Dispositive Power
P	erson		0 shares
With:		8.	Shared Dispositive Power
			3,009,706 shares (1)
9.	Aggreg	gate 1	Amount Beneficially Owned by Each Reporting Person
			hares (1)
10.	Check	if th	e Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)
11.	Percen	t of (Class Represented by Amount in Row 9
	4.1% (2)	
12.	,		porting Person (see instructions)
	PN		

- (1) Consists of 3,009,706 Ordinary Shares held directly by Frazier Life Sciences Public Fund L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund L.P.
- (2) Based on 72,918,994 Ordinary Shares outstanding on September 30, 2021 as set forth in the Issuer's Unaudited Condensed Consolidated Interim Financial Statements for the Three and Nine Months Ended September 30, 2021, which was included as Exhibit A to the Issuer's Form 6-K filed with the SEC on November 3, 2021.

1.	Names	of R	Reporting Persons
	FHML	SP, I	L.L.C.
2.	Check (a) □		Appropriate Box if a Member of a Group (see instructions) (b) ⊠
	(a) ⊔		(0) 🖾
3.	SEC U	SE C	DNLY
4.	Citizen	ship	or Place of Organization
	Delawa	are	
		5.	Sole Voting Power
Niii	mber of		0 shares
S	hares	6.	Shared Voting Power
	eficially ned by		3,009,706 shares (1)
	Each	7.	Sole Dispositive Power
P	porting erson		0 shares
1	With:	8.	Shared Dispositive Power
			3,009,706 shares (1)
9.	Aggreg	gate 1	Amount Beneficially Owned by Each Reporting Person
	3,009,7	⁷ 06 s	hares (1)
10.	Check	if the	e Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)
11.	Percen	t of (Class Represented by Amount in Row 9
	4.1% (2	2)	
12.	Type o	f Rej	porting Person (see instructions)
	00		

- (1) Consists of 3,009,706 Ordinary Shares held directly by Frazier Life Sciences Public Fund L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund L.P.
- (2) Based on 72,918,994 Ordinary Shares outstanding on September 30, 2021 as set forth in the Issuer's Unaudited Condensed Consolidated Interim Financial Statements for the Three and Nine Months Ended September 30, 2021, which was included as Exhibit A to the Issuer's Form 6-K filed with the SEC on November 3, 2021.

1.	. Names of Reporting Persons		
	Frazier	I ifa	e Sciences X, L.P.
2.			
	(a) 🗆		(b) ⊠
3.	SEC U	SF C	ONI V
J.	old o	OL C	
4.	Citizen	ship	or Place of Organization
	Delawa	are	
I		5.	Sole Voting Power
	, ,		0 shares
	mber of hares	6.	Shared Voting Power
	eficially		720.051 shares (1)
Owned by Each		7.	720,951 shares (1) Sole Dispositive Power
Reporting		/ •	Sole Dispositive Fower
Person			0 shares
With:		8.	Shared Dispositive Power
			720,951 shares (1)
9.	Aggreg	gate 1	Amount Beneficially Owned by Each Reporting Person
	720,95	1 sha	ares (1)
10.			e Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)
	П		
11.	_	t of (Class Represented by Amount in Row 9
	1 00/ /	2)	
12.	1.0% (porting Person (see instructions)
14.	1ypc 0		Social Letoon (see monucuono)
	PN		

- (1) Consists of 720,951 Ordinary Shares held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick Heron and James Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.
- (2) Based on 72,918,994 Ordinary Shares outstanding on September 30, 2021 as set forth in the Issuer's Unaudited Condensed Consolidated Interim Financial Statements for the Three and Nine Months Ended September 30, 2021, which was included as Exhibit A to the Issuer's Form 6-K filed with the SEC on November 3, 2021.

1.	Names of Reporting Persons		
	FHML	S X,	L.P.
2.			Appropriate Box if a Member of a Group (see instructions)
	(a) 🗆		(b) ⊠
3.	SEC U	SE C	DNLY
4.	Citizen	ship	or Place of Organization
		Ī	
	Delawa	are 5.	Sole Voting Power
		٥.	Sole voling rower
Nu	mber of		0 shares
	hares	6.	Shared Voting Power
	eficially ned by		720,951 shares (1)
	Each porting	7.	Sole Dispositive Power
P	erson		0 shares
With:		8.	Shared Dispositive Power
			720,951 shares (1)
9.	Aggreg	gate 1	Amount Beneficially Owned by Each Reporting Person
	720,95	1 sha	ares (1)
10.			e Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)
11.	Percen	t of (Class Represented by Amount in Row 9
	1.0% (2)	
12.	,		porting Person (see instructions)
	PN		
	PIN		

- (1) Consists of 720,951 Ordinary Shares held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick Heron and James Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.
- (2) Based on 72,918,994 Ordinary Shares outstanding on September 30, 2021 as set forth in the Issuer's Unaudited Condensed Consolidated Interim Financial Statements for the Three and Nine Months Ended September 30, 2021, which was included as Exhibit A to the Issuer's Form 6-K filed with the SEC on November 3, 2021.

1.	Names of Reporting Persons		
	FHML		
2.	Check (a) □		Appropriate Box if a Member of a Group (see instructions) (b) ⊠
-	0001	CE 6	
3.	SEC U	SE C	DNLY
4.	Citizen	ship	or Place of Organization
	Delawa	are	
		5.	Sole Voting Power
Nui	mber of		0 shares
S	hares	6.	Shared Voting Power
	eficially ned by		720,951 shares (1)
Each Reporting		7.	Sole Dispositive Power
P	erson		0 shares
With:		8.	Shared Dispositive Power
			720,951 shares (1)
9.	Aggreg	gate 1	Amount Beneficially Owned by Each Reporting Person
	720,95	1 sha	ares (1)
10.	Check	if the	e Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)
11.	Percen	t of (Class Represented by Amount in Row 9
	1.0% (2)	
12.	Type o	f Rep	porting Person (see instructions)
	00		

- (1) Consists of 720,951 Ordinary Shares held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick Heron and James Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.
- (2) Based on 72,918,994 Ordinary Shares outstanding on September 30, 2021 as set forth in the Issuer's Unaudited Condensed Consolidated Interim Financial Statements for the Three and Nine Months Ended September 30, 2021, which was included as Exhibit A to the Issuer's Form 6-K filed with the SEC on November 3, 2021.

1.	Names	of R	eporting Persons
	James 1	N. To	ppper
2.			Appropriate Box if a Member of a Group (see instructions)
	(a) □	((b) ⊠
3.	SEC U	SE C	DNLY
	- C1-1	1.	
4.	Citizen	ship	or Place of Organization
	United	State	es Citizen
		5.	Sole Voting Power
».T	1 6		0 shares
	nber of L hares	6.	Shared Voting Power
Ben	eficially		
	ned by	_	3,730,657 shares (1)
	Each porting	7.	Sole Dispositive Power
P	erson		0 shares
V	Vith:	8.	Shared Dispositive Power
			3,730,657 shares (1)
9.	Aggreg	ate A	Amount Beneficially Owned by Each Reporting Person
			hares (1)
10.	Check	if the	e Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)
11.	Percent	of C	Class Represented by Amount in Row 9
	5.1% (2))	
12.			porting Person (see instructions)
	1) PC 0		
	IN		

- (1) Consists of (i) 720,951 Ordinary Shares held directly by Frazier Life Sciences X, L.P. and (ii) 3,009,706 Ordinary Shares held directly by Frazier Life Sciences Public Fund L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund L.P.
- (2) Based on 72,918,994 Ordinary Shares outstanding on September 30, 2021 as set forth in the Issuer's Unaudited Condensed Consolidated Interim Financial Statements for the Three and Nine Months Ended September 30, 2021, which was included as Exhibit A to the Issuer's Form 6-K filed with the SEC on November 3, 2021.

1.	Names	of R	Leporting Persons
	Patrick	J. H	eron
2.			Appropriate Box if a Member of a Group (see instructions)
	(a) □	((b) ⊠
3.	SEC U	SE C	DNLY
4.	Citizen	chin	or Place of Organization
4.	Citizen	ыпр	of Flace of Organization
	United		es Citizen
		5.	Sole Voting Power
Niii	nber of		0 shares
S	hares	6.	Shared Voting Power
	eficially		3,730,657 shares (1)
	ned by Each	7.	Sole Dispositive Power
Reporting		, .	Sole Bispositive Forter
Person With:			0 shares
\ \ \	VIIII:	8.	Shared Dispositive Power
			3,730,657 shares (1)
9.	Aggreg	gate 1	Amount Beneficially Owned by Each Reporting Person
	3 730 <i>6</i>	557 c	hares (1)
10.			e Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)
11	<u> </u>	C <i>(</i>	Elec December 11 Access 12 Dec 0
11.	Percen	i oi (Class Represented by Amount in Row 9
	5.1% (2	2)	
12.	Type o	f Rej	porting Person (see instructions)
	IN		
	11.1		

- (1) Consists of (i) 720,951 Ordinary Shares held directly by Frazier Life Sciences X, L.P. and (ii) 3,009,706 Ordinary Shares held directly by Frazier Life Sciences Public Fund L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund L.P.
- (2) Based on 72,918,994 Ordinary Shares outstanding on September 30, 2021 as set forth in the Issuer's Unaudited Condensed Consolidated Interim Financial Statements for the Three and Nine Months Ended September 30, 2021, which was included as Exhibit A to the Issuer's Form 6-K filed with the SEC on November 3, 2021.

- (1) Consists of 3,009,706 Ordinary Shares held directly by Frazier Life Sciences Public Fund L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund L.P.
- (2) Based on 72,918,994 Ordinary Shares outstanding on September 30, 2021 as set forth in the Issuer's Unaudited Condensed Consolidated Interim Financial Statements for the Three and Nine Months Ended September 30, 2021, which was included as Exhibit A to the Issuer's Form 6-K filed with the SEC on November 3, 2021.

1.	Names	of R	Reporting Persons
	James	Brus	h
2.			Appropriate Box if a Member of a Group (see instructions)
	(a) 🗆		(b) ⊠
3.	SEC U	SE C	DNLY
4.	Citizen	ship	or Place of Organization
	United	Stat	es Citizen
	Officed	5.	Sole Voting Power
	mber of	C	0 shares
	hares eficially	6.	Shared Voting Power
	ned by		3,009,706 shares (1)
	Each	7.	Sole Dispositive Power
	porting erson		0 shares
7	With:	8.	Shared Dispositive Power
			3,009,706 shares (1)
9.	Aggreg	gate 1	Amount Beneficially Owned by Each Reporting Person
	3,009,7	⁷ 06 s	hares (1)
10.			e Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)
11.	Percen	t of (Class Represented by Amount in Row 9
	4.1% (2)	
12.		_	porting Person (see instructions)

	IN		

- (1) Consists of 3,009,706 Ordinary Shares held directly by Frazier Life Sciences Public Fund L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund L.P.
- (2) Based on 72,918,994 Ordinary Shares outstanding on September 30, 2021 as set forth in the Issuer's Unaudited Condensed Consolidated Interim Financial Statements for the Three and Nine Months Ended September 30, 2021, which was included as Exhibit A to the Issuer's Form 6-K filed with the SEC on November 3, 2021.

Item 1(a). Name of Issuer: Autolus Therapeutics plc Item 1(b). Address of Issuer's Principal Executive Offices: The MediaWorks, 191 Wood Lane, London W12 7FP, United Kingdom **Item 2(a).** Name of Person Filing: The entities and persons filing this statement (collectively, the "Reporting Persons") are: Frazier Life Sciences X, L.P. ("FLS X") FHMLS X, L.P. ("FHMLS-X L.P.") FHMLS X, L.L.C. ("FHMLS-X LLC") Frazier Life Sciences Public Fund L.P. ("FLSPF") FHMLSP, L.P. FHMLSP, L.L.C. James N. Topper ("Topper") Patrick J. Heron ("Heron") Albert Cha ("Cha") James Brush ("Brush" and together with Topper, Heron and Cha, the "Members") **Item 2(b).** Address of Principal Business Office or, if none, Residence: The address and principal business office of the Reporting Persons is: c/o Frazier Healthcare Partners 601 Union Street, Suite 3200 Seattle, Washington 98101 Item 2(c). Citizenship: **Entities:** FLS X Delaware, U.S.A. FHMLS-X L.P. Delaware, U.S.A. Delaware, U.S.A. FHMLS-X LLC **FLSPF** Delaware, U.S.A. FHMLSP, L.P. Delaware, U.S.A. FHMLSP, L.L.C. Delaware, U.S.A. United States Citizen Individuals: Topper United States Citizen Heron Cha United States Citizen Brush United States Citizen Item 2(d). Title of Class of Securities: Ordinary Shares Item 2(e). CUSIP Number: 05280R100* * There is no CUSIP number assigned to the ordinary shares. CUSIP number 05280R 100 has been assigned to the American Depositary Shares of the Issuer, which are quoted on the Nasdaq Global Select Market under the symbol "AUTL." Each American Depositary Share represents the right to receive one Ordinary Share of the Issuer.

Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

(a)	\square Broker or dealer registered under Section 15 of the Act (15 U.S.C. 780);
(b)	\square Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	\square Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);
(d)	\square Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)	\square An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);	
(g)	\square A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);	
(h)	\square A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);	
(i)	\square A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);	
(j)	\square A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);	
(k)	\square Group, in accordance with §240.13d–1(b)(1)(ii)(K).	
	If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution:	

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

- (a) Amount Beneficially Owned: See Row 9 of cover page for each Reporting Person.
- **(b)** Percent of Class: See Row 11 of cover page for each Reporting Person
- **(c)** Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.
 - (ii) Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.
 - (iii) Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.
 - (iv) Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.

Item 5. Ownership of 5 Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following \Box .

Item 6. Ownership of More than 5 Percent on Behalf of Another Person

Not applicable.

Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

Item 8. Identification and Classification of Members of the Group

Each member of the group is identified on Exhibit A to this Schedule 13G.

Item 9. Notice of Dissolution of a Group

Not applicable.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and

correct.	
Date: December 17, 2021	FRAZIER LIFE SCIENCES X, L.P. By FHMLS X, L.P., its general partner By FHMLS X, L.L.C., its general partner
	By: /s/ Steve R. Bailey Steve R. Bailey, Chief Financial Officer
	Steve It. Buney, Omer I manetal Officer
Date: December 17, 2021	FHMLS X, L.P. By FHMLS X, L.L.C., its general partner
	By: /s/ Steve R. Bailey
	Steve R. Bailey, Chief Financial Officer
Date: December 17, 2021	FHMLS X, L.L.C.
	By: /s/ Steve R. Bailey
	Steve R. Bailey, Chief Financial Officer
Date: December 17, 2021	FRAZIER LIFE SCIENCES PUBLIC FUND L.P.
	By: FHMLSP, L.P., its General Partner By: FHMLSP, L.L.C., its General Partner
	By: /s/ Steve R. Bailey
	Steve R. Bailey, Chief Financial Officer
Date: December 17, 2021	FHMLSP, L.P.
	By: FHMLSP, L.L.C., its General Partner
	By: /s/ Steve R. Bailey
	Steve R. Bailey, Chief Financial Officer
Date: December 17, 2021	FHMLSP, L.L.C.
	D. (d.Co. D. D.C.)
	By: /s/ Steve R. Bailey Steve R. Bailey, Chief Financial Officer
	Steve It Builey, Omer I manetal Officer
Date: December 17, 2021	By: *
	James N. Topper
Date: December 17, 2021	By: <u>*</u>
	Patrick J. Heron

Date: December 17, 2021		**
		Albert Cha
Date: December 17, 2021	By:	**
		James Brush
Date: December 17, 2021	*Bv:	/s/ Steve R. Bailey

Steve R. Bailey, as Attorney-in-Fact

* This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on February 24, 2017.

^{**} This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021.

Exhibit Index

Exhibit A - Agreement regarding filing of joint Schedule 13G.

AGREEMENT

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Ordinary Shares of Autolus Therapeutics plc.

Date: December 17, 2021

FRAZIER LIFE SCIENCES X, L.P.

By FHMLS X, L.P., its general partner By FHMLS X, L.L.C., its general partner

By: /s/ Steve R. Bailey

Steve R. Bailey, Chief Financial Officer

FHMLS X, L.P.

By FHMLS X, L.L.C., its general partner

By: /s/ Steve R. Bailey

Steve R. Bailey, Chief Financial Officer

FHMLS X, L.L.C.

By: /s/ Steve R. Bailey

Steve R. Bailey, Chief Financial Officer

FRAZIER LIFE SCIENCES PUBLIC FUND L.P.

By: FHMLSP, L.P., its General Partner By: FHMLSP, L.L.C., its General Partner

By: /s/ Steve R. Bailey

Steve R. Bailey, Chief Financial Officer

FHMLSP, L.P.

By: FHMLSP, L.L.C., its General Partner

By: /s/ Steve R. Bailey

Steve R. Bailey, Chief Financial Officer

FHMLSP, L.L.C.

By: /s/ Steve R. Bailey

Steve R. Bailey, Chief Financial Officer

By: *

James N. Topper

Date: December 17, 2021

Date: December 17, 2021		*
		Patrick J. Heron
Date: December 17, 2021	By:	**
		Albert Cha
Date: December 17, 2021	By:	**
		James Brush
Date: December 17, 2021	*By:	/s/ Steve R. Bailey
		Steve R. Bailey, as Attorney-in-Fact

^{*} This Agreement was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on February 24, 2017.

^{**} This Agreement was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021.